How stroma cells trigger tumour angiogenesis
Analyses of the stroma cell proteome have revealed how intratumoral hypoxia triggers the formation of dysfunctional blood vessels that block drugs from entering the tumour and push metastasis.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
Jennewein Biotechnologie expands into Chinese market
Jennewein Biotechnologie and Asia’s largest dairy company Yili Group have joined forces to develop an innovative infant formula tailored to the Chinese market.
Medicxi put €40m into two Sosei spin off companies
Sosei Group Corporation has spun out two programmes of its neurology pipeline into two newly created companies funded by venture fund Medicxi.
EMA greenlights two orphan drugs and two biosimilars
EMA’s human medicines committee (CHMP) recommended six medicines for approval at its January 2019 meeting.
Hitachi expands European reach in cell and gene therapy
Hitachi Chemical Co. Ltd. is set to takeover cell and gene therapy CDMO apceth Biopharma GmbH to get a foothold in Europe, the second largest market for advanced therapies after the US.
Dewpoint Therapeutics kicks off with $60m financing
Dewpoint Therapeutics has attracted interested of investors with a completely new approach that might cure a huge array of devasting diseases.
IPO: Marinomed sets offer price
Marinomed has set the offer price for its IPO at Vienna Stock Exchange at the lower limit of €75 per new share.
Can machines learn to discover drugs?
Take the right dataset, add an ingenious algorithm or two – and voilá! Your billion-euro blockbuster molecule is ready! AI-driven drug development is exciting investor interest, while Big Pharma is also asking what forms of artifical intelligence can be slotted in at what stages in the process. AI-powered drug repurposing has seen some candidates enter clinical stage testing, but it’s still unclear whether the technology is already powerful enough for de novo molecule discovery.
Novozymes partners with Carbios subsidiary Carbiolice
Novozymes has entered into a partnership with French Carbios and its subsidiary Carbiolice, which aim to launch degradable bioplastics with limited lifespan for the packaging industry by 2020.
Biomarker predicts response to TNF blockers
A new assay that accurately measures how arthritis patients respond to treatment with TNFalpha blockers such as adalimumab, open up the way to predict efficacy.